danish
pharmaceuticals
biotechnology
group
novo
nordisk
said
tuesday
ready
buy
new
business
suitable
did
rule
possibility
merger
right
partner
appeared
current
phase
good
funds
available
possibility
acquiring
new
products
firms
crops
core
activity
areas
novo
nordisk
deputy
chief
executive
kurt
anker
nielsen
told
reuters
interview
power
asking
anybody
permission
said.novo
nordisk
capital
end-1996
stood
72
percent
balance
group
just
negotiated
new
credit
facilities
600
million
club
firm
activities
fitted
novo
nordisk
gentofte
work
aim
nielsen
said.the
original
novo
industri
merged
denmark
nordisk
gentofte
1989
world
leader
insulin
industrial
enzyme
products.nielsen
adamant
novo
nordisk
consider
merging
kept
independence
equal
partner.he
added
novo
nordisk
capital
structure
excessively
heavy
especially
group
aimed
having
capital
60-65
percent
balance
reduced
liquidity
form
securities
things
felt
novo
nordisk
big
recognised
firm
conduct
financing
operations
outside
balance
said.novo
nordisk
core
business
activities
diabetes
care
women
hormone
replacement
products
human
growth
hormones
industrial
enzymes
said
size
absolutely
vital
reckon
important
big
selected
product
areas
way
just
risk
forced
arms
big
global
players
nielsen
said.novo
nordisk
recently
set
annual
growth
targets
biggest
activities
industrial
enzymes
diabetes
treatment
10-15
percent
7-10
percent
respectively.hormone
replacement
products
women
seen
growing
10-15
percent
said
growth
hormones
expected
quite
well.novo
nordisk
said
considered
united
states
20
percent
diabetes
care
market
offering
greatest
growth
potential
key
insulin
products.on
march
12
novo
nordisk
posted
bumper
pre
tax
profit
2.521
billion
crowns
17
percent
1995
percent
higher
consolidated
turnover
14.873
billion
crowns
forecast
solid
progress
continuing
1997
copenhagen
newsroom
45-33969653
